Estradiol
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Estradiol is the primary and most potent endogenous estrogen, used in hormone replacement therapy (HRT) for menopausal symptoms including vasomotor symptoms (hot flashes), vulvovaginal atrophy, and osteoporosis prevention. Transdermal and oral formulations are available. The Women's Health Initiative (WHI) reshaped prescribing practices. Current guidelines favor the lowest effective dose for the shortest duration, with transdermal delivery preferred for reduced thrombotic risk.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Estradiol is the primary and most potent endogenous estrogen, used in hormone replacement therapy (HRT) for menopausal symptoms including vasomotor symptoms (hot flashes), vulvovaginal atrophy, and osteoporosis prevention. NutriStack rates the supporting evidence as strong. Common adult dosing is Oral: 0.5–2 mg daily; Transdermal patch: 0.025–0.1 mg/day (applied once or twice weekly); Topical gel varies by product (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: effective relief of vasomotor symptoms (hot flashes, night sweats), treatment of vulvovaginal atrophy and urogenital symptoms, prevention of postmenopausal osteoporosis. 10 sources indexed (2015–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Binds to estrogen receptors (ER-alpha and ER-beta) in target tissues including the hypothalamus, uterus, breast, bone, cardiovascular system, and brain. The estrogen-receptor complex modulates gene transcription, maintaining reproductive tissue integrity, promoting bone density by inhibiting osteoclast activity, supporting vasomotor stability through hypothalamic thermoregulatory centers, and regulating lipid metabolism. Also has non-genomic rapid signaling effects on vascular endothelium.6,8
Dosing & protocol.
Oral: can be taken with or without food. Transdermal: apply to clean, dry skin of lower abdomen or buttock; rotate sites. Topical gel: apply to arm or thigh as directed.5
Full safety detail.
Side effects
- Breast tenderness and enlargement
- Nausea (oral route)
- Headache
- Bloating and fluid retention
- Irregular bleeding or spotting
- Venous thromboembolism (DVT/PE, primarily oral route)
- Skin irritation (transdermal)
- Mood changes
Contraindications
- Known or suspected breast cancer or estrogen-dependent neoplasia3
- Active or history of venous thromboembolism (DVT/PE) or arterial thromboembolic disease (stroke, MI)10
- Undiagnosed abnormal genital bleeding
- Known or suspected pregnancy
- Active liver disease or hepatic impairment
- Known protein C, protein S, or antithrombin deficiency or other thrombophilias
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
5- 1Estradiol Concentrations for Adequate Gender-Affirming Feminizing Therapy: A Systematic ReviewPMIDWinston-McPherson GN, Thomas TA, Krasowski MD et al. · LGBT health · 2025
Winston-McPherson GN, Thomas TA, Krasowski MD et al.. Estradiol Concentrations for Adequate Gender-Affirming Feminizing Therapy: A Systematic Review. LGBT health. 2025
- 2Measurements of Postmenopausal Serum Estradiol Levels and Cardiovascular Events: A Systematic ReviewPMIDGulamhusein N, Miranda KT, Ahmed SB et al. · CJC open · 2024
Gulamhusein N, Miranda KT, Ahmed SB et al.. Measurements of Postmenopausal Serum Estradiol Levels and Cardiovascular Events: A Systematic Review. CJC open. 2024
- 3Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-AnalysisPMIDComini ACM, Carvalho BM, Moreira MJB et al. · Clinical breast cancer · 2023
Comini ACM, Carvalho BM, Moreira MJB et al.. Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis. Clinical breast cancer. 2023
- 4Association Between Estradiol and Human Aggression: A Systematic Review and Meta-AnalysisPMIDWang Y, Wang H, Cai J et al. · Psychosomatic medicine · 2023
Wang Y, Wang H, Cai J et al.. Association Between Estradiol and Human Aggression: A Systematic Review and Meta-Analysis. Psychosomatic medicine. 2023
- 5Low-dose transdermal estradiol for vasomotor symptoms: a systematic reviewPMIDCorbelli J, Shaikh N, Wessel C et al. · Menopause (New York, N.Y.) · 2015
Corbelli J, Shaikh N, Wessel C et al.. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause (New York, N.Y.). 2015
Reviews & position papers
2- 6Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestinsPMIDGraham S, Archer DF, Simon JA et al. · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2022
Graham S, Archer DF, Simon JA et al.. Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2022
- 7Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine FibroidsPMIDSyed YY · Drugs · 2022
Syed YY. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids. Drugs. 2022
Reference material
3- 8Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women (WHI). JAMA. 2002;288(3):321-333.Source linkedPMID
- 9The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.Source linkedPMID
- 10Canonico M et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens. Circulation. 2007;115(7):840-845.Source linkedPMID
Common questions.
Quick answers about Estradiol, drawn from the data on this page.
What is Estradiol?
Estradiol is the primary and most potent endogenous estrogen, used in hormone replacement therapy (HRT) for menopausal symptoms including vasomotor symptoms (hot flashes), vulvovaginal atrophy, and osteoporosis prevention. Transdermal and oral formulations are available. The Women's Health Initiative (WHI) reshaped prescribing practices. Current guidelines favor the lowest effective dose for the shortest duration, with transdermal delivery preferred for reduced thrombotic risk.
What is Estradiol used for?
Commonly cited benefits of Estradiol include: Effective relief of vasomotor symptoms (hot flashes, night sweats); Treatment of vulvovaginal atrophy and urogenital symptoms; Prevention of postmenopausal osteoporosis; Improvement in mood and sleep quality; Favorable effects on lipid profile. NutriStack rates the overall evidence as strong.
What is a typical dose of Estradiol?
A typical adult dose of Estradiol is Oral: 0.5–2 mg daily; Transdermal patch: 0.025–0.1 mg/day (applied once or twice weekly); Topical gel varies by product (as prescribed by your physician). The commonly recommended form is Transdermal patch preferred (lower thrombotic risk); oral tablet; topical gel or spray. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Estradiol?
Reported side effects include breast tenderness and enlargement, nausea (oral route), headache, bloating and fluid retention, irregular bleeding or spotting, venous thromboembolism (dvt/pe, primarily oral route). This is educational information; check with a healthcare professional before use.
How strong is the evidence for Estradiol?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Estradiol in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.